it does seem to me that as soon as you start 'combination' studies ie combining ivx043 with a checkpoint inhibitor, that maybe research on the primary input ie ivx043 is perhaps waning...who knows? Also, a string of announcements of new shares or options issued to directors must surely give everyone a distinct pain in the posterior. Glad to be out.
